NYSE:DHRLife Sciences
Do Danaher’s Bioprocessing Gains and Buybacks Reveal a Sharper Strategic Focus for DHR?
Danaher Corporation recently reported full-year 2025 results, with sales rising to US$24.57 billion while net income and earnings per share from continuing operations declined modestly versus the prior year.
Management pointed to resilient demand in bioprocessing consumables and diagnostics, alongside renewed share buybacks and 2026 guidance, underscoring its focus on innovation and productivity amid muted but stable research funding.
We’ll now explore how Danaher’s emphasis on bioprocessing...